Intercept Pharmaceuticals (ICPT) Outlook Unchanged Following Earnings - Baird
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Intercept Pharma (ICPT) Advances to Session High
November 10, 2015 11:05 AM ESTIntercept Pharma (NASDAQ: ICPT) hit session highs Tuesday morning, rising 12%.
... MoreIntercept (ICPT) Waiting for Catalysts - Cowen
November 10, 2015 9:39 AM ESTIntercept Pharmaceuticals (NASDAQ: ICPT) reported Q3 EPS of ($2.10) vs consensus of ($2.74). As of September 30, 2015, ICPT had cash of $695.7M and cash burn was $36.5M. The net loss increase was primarily the result of increases in G&A expenses related to ICPT's corporate and pre-commercial activities.
Intercept projects adjusted operating expenses for the year ending December 31, 2015 will be below its... More
Needham & Company Reiterates Buy on Intercept (ICPT) Following Q3 Update
November 9, 2015 2:21 PM ESTNeedham & Company analyst Alan Carr reiterating a Buy rating and $500 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) following earnings and the company's corporate update today.
Carr commented, "Intercept mgmt provided a 3Q15 corporate update this morning. Key upcoming milestones include the Obeticholic... More
Intercept Pharma (ICPT) Posts Narrwer-than-Expected Q3 Loss
November 9, 2015 9:14 AM ESTIntercept Pharma (NASDAQ: ICPT) reported Q3 EPS of ($2.10), $0.65 better than the analyst estimate of ($2.75). Revenue for the quarter came in at $445 thousand versus the consensus estimate of $420 thousand.
As of September 30, 2015, Intercept had cash, cash equivalents and investment securities available for sale of approximately... More
